Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimensNEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.…
• Clinical data demonstrated administration of AGA2115 drove dose-dependent increases in bone mineral density • The Company and collaborators also…
124I-evuzamitide, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients…
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA…
Company to highlight ongoing AXPAXLI™ wet AMD registrational program, strategy and next steps in NPDR and DME, and global commercial…
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo…
Is the DEA the Epitome of Ineptitude?"Why is the VA importing cannabis that U.S. companies have been ready to produce…
Hemogenyx Pharmaceuticals Announces Manufacturing Partnership with Made Scientific to Advance HG-CT-1 CAR-T Therapy CITY OF LONDON, GB / ACCESS Newswire…
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5…